R&D | October 12, 2025
Merck unveils new HIV treatment and prevention data at EACS 2025
Merck will showcase results in innovative solutions in HIV treatment and prevention
Merck will showcase results in innovative solutions in HIV treatment and prevention
The company will present new data from across over 20 cancer types and multiple treatment settings at European Society for Medical Oncology Congress 2025
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Merck and Siemens signed new MoU extending their strategic partnership to accelerate digital transformation in the life science industry
Keytruda Qlex is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute
Merck opens first climate-neutral manufacturing facility in Ireland
Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
He has successfully led the development of 15 approved drugs worldwide across various therapeutic areas over his more than 20-year career
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Subscribe To Our Newsletter & Stay Updated
